EVALUASI PENGGUNAAN TERAPI OBAT KARDIOVASKULAR PADA PASIEN HIPERTENSI YANG DIRAWAT DI RSUP  DR. M. DJAMIL PADANG

Elsa Marsellinda; Dhea Suci Aulia

doi:10.36805/jbf.v4i3.1121

Elsa Marsellinda Prodi Farmasi Klinis Fakultas Ilmu Kesehatan Universitas Baiturrahmah Padang
Dhea Suci Aulia Prodi Farmasi Klinis Fakultas Ilmu Kesehatan Universitas Baiturrahmah Padang

DOI: https://doi.org/10.36805/jbf.v4i3.1121

Kata Kunci: anti hipertensi, jenis kelamin, usia

Abstrak

Hipertensi adalah salah satu faktor risiko utama yang dapat dimodifikasi yang terkait dengan penyakit kardiovaskular, dan prevalensi serta tingkat keparahannya meningkat seiring bertambahnya usia. Tujuan penelitian ini adalah untuk melihat gambaran penggunaan terapi obat hipertensi, jenis kelamin dan tingkat usia pasien yang dirawat di RSUP dr. M. Djamil Padang Periode Oktober-Desember 2023. Data dikumpulkan secara retrospektif dari rekam medis pasien hipertensi yang dirawat bangsal penyakit dalam. periode Oktober sampai Desember 2023 dianalisis secara deskriptif. Berdasarkan hasil dari penelitian dari 131 pasien hipertensi yang di Rawat di RSUP DR. M.Djamil Padang Periode Oktober-Desember 2023 disimpulkan yaitu pasien jenis kelamin laki – laki lebih banyak dari pada perempuan, berdasarkan usia pasien dengan rentang usia 56 – 65 tahun dan penggunaan terapi antihipertensi paling banyak digunakan adalah 3 kombinasi

Referensi

Centers for Disease Control and Prevention. (2016) ‘Protocol for Controlling Hypertension in Adults.’, p. 2.

Chruściel, P. et al. (2022) ‘Clinical research

Associations between the lipid profile and the development of hypertension in young individuals – the preliminary study’, 18 (1):, pp. 25–35.

Defianna, S.R. et al. (2021) ‘Gender differences in

prevalence and risk factors for hypertension among adult populations: A cross-sectional study in indonesia’, International Journal of Environmental Research and Public Health, 18(12). Available at: https://doi.org/10.3390/ijerph18126259.

Heni Setyoningsih (2022) ‘Hubungan Interaksi Obat Terhadap Efektivitas Obat’, 6(1), pp. 76–88.

Kemenkes (2023) ‘Survei Kesehatan Indonesia

Tahun 2023’, Badan Kebijakan Pembangunan Kesehatan Tim Penyusun Ski 2023 Dalam Angka, pp. 1–68.

Khairiyah, U., Yuswar, M.A. and Purwanti, N.U.

(2022) ‘Pola Penggunaan Obat Antihipertensi Pada Pasien Hipertensi di Instalasi Rawat Jalan Rumah Sakit’, Jurnal Syifa Sciences and Clinical Reasearch (JSSCR), 4(3), pp. 609–617.

El Khoudary, S.R. et al. (2020) ‘Menopause

Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement from the American Heart Association’, Circulation, 142(25), pp. E506–E532. Available at: https://doi.org/10.1161/CIR.000000000000 0912.

Kim, C. et al. (2023) ‘Women’s Reproductive

Milestones and Cardiovascular Disease Risk: A Review of Reports and Opportunities From the CARDIA Study’, Journal of the American Heart Association, 12(5), pp. 1–19. Available at: https://doi.org/10.1161/JAHA.122.028132.

Lauder, L. et al. (2023) ‘Hypertension management

in patients with cardiovascular comorbidities’, European Heart Journal, 44(23), pp. 2066–2077. Available at: https://doi.org/10.1093/eurheartj/ehac395.

Madania et al. (2022) ‘Potensi Interaksi Obat Pasien

Hipertensi Dan Diabetesmelitus Tipe2 Di Instalasi Rawat Jalan Rsud Toto Kabila’, Pharmacoscript, 5(1), pp. 56–62.

Mannan, A. et al. (2022) ‘Association between comorbidity and health-related quality of life in a hypertensive population: a hospital- based study in Bangladesh’, BMC Public Health, 22(1), pp. 1–12. Available at: https://doi.org/10.1186/s12889-022-12562-w.

Marx, N. et al. (2023) ‘2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology’, European Heart Journal, 44(39), pp. 4043–4140.

Mills, K.T., Stefanescu, A. and He, J. (2020) ‘The

global epidemiology of hypertension’, Nature Reviews Nephrology, 16(4), pp. 223– 237. Available at: https://doi.org/10.1038/s41581-019-0244-2.

Neutel, J.M. and Smith, D.H.G. (2020) ‘

Hypertension management: Rationale for triple therapy based on mechanisms of action’, Cardiovascular Therapeutics, 31(5), pp. 251–258. Available at: https://doi.org/10.1111/1755-5922.12015.

Sakti Pambudi, R. and Rista Rini, H. (2024) ‘Indonesian Journal of Pharmacy and Natural Product Potensi Interaksi Penggunaan Obat Antihipertensi di Klinik X Tahun 2023 Potential Interactions with the Use of Antihypertensive Drugs at Clinic X Boyolali in 2023’, 07, pp. 41–46.

Volpe, M., Gallo, G. and Tocci, G. (2020) ‘Trends

in Cardiovascular Medicine New approach to blood pressure control : Triple combination pill ✩’, Trends in Cardiovascular Medicine, 30(2), pp. 72–77. Available at: https://doi.org/10.1016/j.tcm.2019.03.002.

WHO (2023) ‘Afghanistan Albania Hypertension profile’, (2019).

Wierzejska, E. et al. (2020) ‘Systematic review / Meta-analysis A global perspective on the costs of hypertension : a s ystematic review’, Arch Med Sci, 16, pp. 1078–1091.

Zaman, M.A. et al. (2023) ‘Comparing Triple

Combination Drug Therapy and Traditional Monotherapy for Better Survival in Patients With High-Risk Hypertension : A Systematic Review’, 15(7). Available at: https://doi.org/10.7759/cureus.41398.